ENANTA PHARMACEUTICALS, INC Income Taxes Paid, Net
ENANTA PHARMACEUTICALS, INC (ENTA) reported Income Taxes Paid, Net of $12.62 million for the 12-month period ending 2016-09-30, per its 10-K filed 2016-12-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2016-12-09
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for the quarter ending 2016-09-30 was $3.50M, a 591.70% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for the quarter ending 2016-06-30 was $3.40M, a 80.54% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for the quarter ending 2016-03-31 was $4.00K, a 99.98% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for the quarter ending 2015-12-31 was $5.71M, a 8546.97% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for fiscal 2016 was $12.62M, a 68.52% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for fiscal 2015 was $40.07M, a 26975.68% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC income taxes paid, net for fiscal 2014 was $148.00K.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2016-09-30 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $6.91M derived: sum of 2 quarters · filed 2016-12-09 | $6.91M derived: sum of 3 quarters · filed 2016-12-09 | $12.62M 10-K · filed 2016-12-09 |
| 2016-06-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $3.41M derived: sum of 2 quarters · filed 2016-08-09 | $9.12M 10-Q · filed 2016-08-09 | $9.62M derived: sum of 4 quarters · filed 2016-12-09 |
| 2016-03-31 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $5.71M 10-Q · filed 2016-05-10 | $6.22M derived: sum of 3 quarters · filed 2016-12-09 | $23.72M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-12-31 | $5.71M 10-Q · filed 2016-02-09 | $6.21M derived: sum of 2 quarters · filed 2016-12-09 | $23.71M derived: sum of 3 quarters · filed 2016-12-09 | $45.71M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-09-30 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $18.01M derived: sum of 2 quarters · filed 2016-12-09 | $40.01M derived: sum of 3 quarters · filed 2016-12-09 | $40.07M 10-K · filed 2016-12-09 |
| 2015-06-30 | $17.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $39.50M derived: sum of 2 quarters · filed 2016-08-09 | $39.57M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $22.07M 10-Q · filed 2016-05-10 | ||
| 2014-12-31 | $66.00K 10-Q · filed 2016-02-09 | |||
| 2014-09-30 | $148.00K 10-K · filed 2016-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |